A Phase 2 Randomized, Double-blind, Placebo-controlled Study Assessing Analgesic Efficacy and Safety of the Novel Non-opioid SRP-001 Compared to Placebo in Patients With Moderate-to-severe Acute Postoperative Pain After Impacted Third Mandibular Molar Extraction
South Rampart Pharma, Inc.
Summary
This study tests whether a single oral dose of SRP-001 (2,000 mg), a non-opioid drug, relieves moderate-to-severe pain after surgery to remove impacted third molars (wisdom teeth), compared with placebo. It also evaluates safety and how the body processes the drug.
Description
This is a single-center, randomized, double-blind, placebo-controlled, parallel-group Phase 2 study evaluating the analgesic efficacy, onset of action, pharmacokinetics, and safety of a single oral dose of SRP-001 (2,000 mg oral suspension) compared to matching placebo in 130 adult participants experiencing moderate-to-severe acute postoperative pain (NPRS ≥ 5 and categorical pain ≥ 2 within 4.5 hours) following extraction of two or more third molars (including at least two bone-impacted mandibular molars). Participants remain in the clinical research unit for 12 hours post-dose for serial eff…
Eligibility
- Age range
- 18–50 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Is male or female ≥ 18 and ≤ 50 years of age. * Requires extraction of 2 or more third molars. At least 2 of the third molars must be a fully or partially bone impacted mandibular molar. * Experiences moderate-to-severe pain defined as a score ≥ 2 on the 4-point categorical scale, and a score of ≥ 5 measured by the 0-10 Numeric Pain Rating Scale (NPRS) within 4.5 hours after surgery. * Has a body weight ≥ 45 kg and a body mass index (BMI) ≤ 35 kg/m2. * Female subjects of child-bearing potential must have used an acceptable method of contraception for at least 30 days pri…
Interventions
- DrugSRP-001
SRP-001 Oral Suspension
- DrugMatching Placebo for SRP-001
Matching Placebo for SRP-001 Oral Suspension
Location
- CenExel JBR Clinical ResearchSalt Lake City, Utah